Literature DB >> 20512080

Optimal buffer choice of the radiosynthesis of (68)Ga-Dotatoc for clinical application.

Matthias Bauwens1, Rufael Chekol, Hubert Vanbilloen, Guy Bormans, Alfons Verbruggen.   

Abstract

OBJECTIVES: (68)Ga-Dotatoc has become the PET radiopharmaceutical of choice for the diagnosis and treatment follow-up of neuroendocrine tumours. (68)Ga-Dotatoc is prepared on-site through a so-called magisterial preparation. The use of an appropriate buffer during the radiolabelling step is essential to maximize the labelling yield and the specific activity. Such a buffer should be nontoxic, able to buffer in the pH range of 3.5-5.0, not compete with gallium ions and preferentially have a weak metal complexing capacity to avoid the formation of colloidal gallium. In addition, the buffer should be allowed for human use. In view of the high radiation dose to the operator when manually handling (68)Ga, especially to the extremities, we also tested the buffers in a semi-automated system.
METHODS: HEPES, acetate, succinate, Tris, glutamate, lactate, oxalate and tartrate were tested as potential buffers in the manual radiosynthesis of (68)Ga-Dotatoc. Temperature, heating time and substrate concentration were optimized.
RESULTS: Buffers based on HEPES, acetate and succinate were found to be the most appropriate. Optimal labelling yields were achieved with a 5-min heating time for the manual synthesis and 8 min for a semi-automated system, whereas the optimal amount of Dotatoc was 30 and 40 microg, respectively.
CONCLUSION: Although the use of HEPES, acetate and succinate as buffering substances yielded comparable results, only acetate is currently recognized as a substance for pharmaceutical use and also for human use. Therefore, acetate buffer should be used for (68)Ga-Dotatoc synthesis. The semi-automated system allowed for a shorter radiosynthesis time, thereby increasing the overall yield.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20512080     DOI: 10.1097/MNM.0b013e32833acb99

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  14 in total

Review 1.  Feasibility and availability of ⁶⁸Ga-labelled peptides.

Authors:  Clemens Decristoforo; Roger D Pickett; Alfons Verbruggen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

Review 2.  The next generation of positron emission tomography radiopharmaceuticals in oncology.

Authors:  Samuel L Rice; Celeste A Roney; Pierre Daumar; Jason S Lewis
Journal:  Semin Nucl Med       Date:  2011-07       Impact factor: 4.446

Review 3.  Good practices for 68Ga radiopharmaceutical production.

Authors:  Bryce J B Nelson; Jan D Andersson; Frank Wuest; Sarah Spreckelmeyer
Journal:  EJNMMI Radiopharm Chem       Date:  2022-10-22

4.  Good manufacturing practice production of [(68)Ga]Ga-ABY-025 for HER2 specific breast cancer imaging.

Authors:  Irina Velikyan; Anders Wennborg; Joachim Feldwisch; Henrik Lindman; Jörgen Carlsson; Jens Sörensen
Journal:  Am J Nucl Med Mol Imaging       Date:  2016-04-24

5.  In-vivo detection of the erythropoietin receptor in tumours using positron emission tomography.

Authors:  Felix Fuge; Dennis Doleschel; Anne Rix; Felix Gremse; Axel Wessner; Oliver Winz; Felix Mottaghy; Wiltrud Lederle; Fabian Kiessling
Journal:  Eur Radiol       Date:  2014-09-09       Impact factor: 5.315

6.  Evaluation of a PACAP Peptide Analogue Labeled with (68)Ga Using Two Different Chelating Agents.

Authors:  Pardeep Kumar; Sushil Kumar Tripathi; Chang-Po Chen; Neil Mehta; Bishnuhari Paudyal; Eric Wickstrom; Mathew L Thakur
Journal:  Cancer Biother Radiopharm       Date:  2016-02       Impact factor: 3.099

7.  Radiation exposure to nuclear medicine personnel handling positron emitters from Ge-68/Ga-68 generator.

Authors:  Durgesh Kumar Dwivedi; Alok Kumar Dwivedi; Satya Pal Lochab; Rakesh Kumar; Niraj Naswa; Punit Sharma; Arun Malhotra; Guru Pad Bandopadhayaya; Chandrashekhar Bal; Gauri Shankar Pant
Journal:  Indian J Nucl Med       Date:  2011-04

Review 8.  Prospective of ⁶⁸Ga-radiopharmaceutical development.

Authors:  Irina Velikyan
Journal:  Theranostics       Date:  2013-12-10       Impact factor: 11.556

9.  Preclinical Study of 68Ga-DOTATOC: Biodistribution Assessment in Syrian Rats and Evaluation of Absorbed Dose in Human Organs.

Authors:  Mojdeh Naderi; Samaneh Zolghadri; Hassan Yousefnia; Ali Ramazani; Amir Reza Jalilian
Journal:  Asia Ocean J Nucl Med Biol       Date:  2016

10.  Development and evaluation of a rapid analysis for HEPES determination in 68Ga-radiotracers.

Authors:  Sarah Pfaff; Tina Nehring; Verena Pichler; Jens Cardinale; Markus Mitterhauser; Marcus Hacker; Wolfgang Wadsak
Journal:  EJNMMI Res       Date:  2018-10-23       Impact factor: 3.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.